Treat-and-extend therapy with aflibercept for diabetic macular edema: a prospective clinical trial

[1]  C. Sotozono,et al.  Prospective Clinical Trial of Intravitreal Aflibercept Treat-and-extend Regimen for Diabetic Macular Edema: 1-Year Outcomes , 2020, Korean journal of ophthalmology : KJO.

[2]  T. Hikichi,et al.  Real-world management of treatment-naïve diabetic macular oedema: 2-year visual outcome focusing on the starting year of intervention from STREAT-DMO study , 2020, British Journal of Ophthalmology.

[3]  Y. Kurimoto,et al.  Efficacy and Safety of Intravitreal Aflibercept Treat-and-Extend Regimens in Exudative Age-Related Macular Degeneration: 52- and 96-Week Findings from ALTAIR , 2020, Advances in Therapy.

[4]  Sung Who Park,et al.  One-Year Results of Treatment of Diabetic Macular Edema with Aflibercept Using the Treat-and-Extend Dosing Regimen: the VIBIM Study , 2020, Ophthalmologica.

[5]  T. Hikichi,et al.  Real-world management of treatment-naïve diabetic macular oedema in Japan: two-year visual outcomes with and without anti-VEGF therapy in the STREAT-DME study , 2019, British Journal of Ophthalmology.

[6]  P. Sanfilippo,et al.  Clinical Outcomes of a Treat and Extend Regimen with Intravitreal Aflibercept Injections in Patients with Diabetic Macular Edema: Experience in Clinical Practice , 2019, Ophthalmology and Therapy.

[7]  J. Chhablani,et al.  Real-world outcomes of non-responding diabetic macular edema treated with continued anti-VEGF therapy versus early switch to dexamethasone implant: 2-year results , 2019, Acta Diabetologica.

[8]  J. S. Gandhi.  Anti-Vascular Endothelial Growth Factor Treatment for Diabetic Macular Edema in a Real-World Clinical Setting. , 2019, American journal of ophthalmology.

[9]  S. Wolf,et al.  One-Year Results of Using a Treat-and-Extend Regimen without a Loading Phase with Anti-VEGF Agents in Patients with Treatment-Naive Diabetic Macular Edema , 2019, Ophthalmologica.

[10]  M. Shimura,et al.  Clinical preferences and trends of anti‐vascular endothelial growth factor treatments for diabetic macular edema in Japan , 2018, Journal of diabetes investigation.

[11]  G. Pertile,et al.  Anti-Vascular Endothelial Growth Factor Treatment for Diabetic Macular Edema in a Real-World Clinical Setting. , 2018, American journal of ophthalmology.

[12]  Jennifer K. Sun,et al.  Early Response to Anti-Vascular Endothelial Growth Factor and Two-Year Outcomes Among Eyes With Diabetic Macular Edema in Protocol T. , 2018, American journal of ophthalmology.

[13]  M. Sugimoto,et al.  Effect of Leaking Foveal Microaneurysms on the Treatment of Center-Involving Diabetic Macular Edema: A Pilot Study , 2018, Ophthalmic Research.

[14]  H. Tanihara,et al.  Treat‐and‐extend versus every‐other‐month regimens with aflibercept in age‐related macular degeneration , 2018, Acta ophthalmologica.

[15]  Rishi P. Singh,et al.  Outcomes of Diabetic Macular Edema Eyes with Limited Early Response in the VISTA and VIVID Studies. , 2017, Ophthalmology. Retina.

[16]  Takao Hirano,et al.  CHANGES IN PLASMA VASCULAR ENDOTHELIAL GROWTH FACTOR LEVEL AFTER INTRAVITREAL INJECTION OF BEVACIZUMAB, AFLIBERCEPT, OR RANIBIZUMAB FOR DIABETIC MACULAR EDEMA , 2017, Retina.

[17]  M. Maia,et al.  Multicenter, Randomized Clinical Trial to Assess the Effectiveness of Intravitreal Injections of Bevacizumab, Triamcinolone, or Their Combination in the Treatment of Diabetic Macular Edema. , 2017, Ophthalmic surgery, lasers & imaging retina.

[18]  Beau B. Bruce,et al.  Randomized Trial of Treat and Extend Ranibizumab with and without Navigated Laser for Diabetic Macular Edema: TREX-DME 1 Year Outcomes. , 2017, Ophthalmology.

[19]  P. Kaiser,et al.  Intravitreal Aflibercept for Diabetic Macular Edema: 148-Week Results from the VISTA and VIVID Studies. , 2016, Ophthalmology.

[20]  A. Wenzel,et al.  Baseline visual acuity strongly predicts visual acuity gain in patients with diabetic macular edema following anti-vascular endothelial growth factor treatment across trials , 2016, Clinical ophthalmology.

[21]  K. Park,et al.  Intraocular Pharmacokinetics of Intravitreal Aflibercept (Eylea) in a Rabbit Model. , 2016, Investigative ophthalmology & visual science.

[22]  M. Sugimoto,et al.  Effect of leaking perifoveal microaneurysms on resolution of diabetic macular edema treated by combination therapy using anti-vascular endothelial growth factor and short pulse focal/grid laser photocoagulation , 2016, Japanese Journal of Ophthalmology.

[23]  R. Apte,et al.  A systematic review of as needed versus treat and extend ranibizumab or bevacizumab treatment regimens for neovascular age-related macular degeneration , 2015, British Journal of Ophthalmology.

[24]  Carsten Framme,et al.  TREAT-AND-EXTEND REGIMENS WITH ANTI-VEGF AGENTS IN RETINAL DISEASES: A Literature Review and Consensus Recommendations , 2015, Retina.

[25]  J. Sorof,et al.  Anti-vascular endothelial growth factor therapy for diabetic macular edema , 2013, Therapeutic advances in endocrinology and metabolism.

[26]  Q. Nguyen,et al.  Long-term outcomes of ranibizumab therapy for diabetic macular edema: the 36-month results from two phase III trials: RISE and RIDE. , 2013, Ophthalmology.

[27]  Ursula Schmidt-Erfurth,et al.  One-year outcomes of the da Vinci Study of VEGF Trap-Eye in eyes with diabetic macular edema. , 2012, Ophthalmology.

[28]  Ursula Schmidt-Erfurth,et al.  The DA VINCI Study: phase 2 primary results of VEGF Trap-Eye in patients with diabetic macular edema. , 2011, Ophthalmology.

[29]  M. Maia,et al.  Primary intravitreal bevacizumab for diffuse diabetic macular edema: the Pan-American Collaborative Retina Study Group at 24 months. , 2009, Ophthalmology.

[30]  Photocoagulation for diabetic macular edema. Early Treatment Diabetic Retinopathy Study report number 1. Early Treatment Diabetic Retinopathy Study research group. , 1985, Archives of ophthalmology.